SEP 16, 2015
C&EN's Virtual Symposium: Advances in Drug Discovery and Development
5 26 8924

C&EN is delighted to present its second annual virtual symposium highlighting groundbreaking research in drug discovery, chemical synthesis, informatics and drug development.

On September 16, 2015, a renowned group of scientists from biotech, pharma and academia will present the latest research findings and new technologies that are driving the design, discovery and development of new drugs – from traditional small molecules and biologics to cutting-edge gene-editing and immunological technologies. Speakers will present the latest advances in identifying promising drug targets, verifying lead compounds, and new strategies that are delivering more powerful, personalized drugs to the marketplace.

Last year, more than 7,400 scientists signed up to attend C&EN’s inaugural virtual event. We invite you to join an even larger audience this September. If you can’t make the live lectures, all presentations will be archived and available on demand for three months.

PROGRAM
This year’s keynote and event speakers are driving R&D inside leading commercial and academic institutions, including Merck, Pfizer, Genentech, Editas Medicine, BIND Therapeutics, Syros, The Scripps Research Institute, and many more. Among the many themes to be covered are:

*Organic synthesis for novel drugs
*Personalized and precision medicine
*Structure-based drug design
*Business and collaborative strategies
*Gene regulation in cancer
*Informatics in the R&D environment
*Genome editing technologies

REGISTRATION

Register now for free, then log in on September 16 to visit the virtual conference and trade show. It’s like being there but without the cost or hassle of travel! Listen to 1-2 key talks or attend a stream of presentations throughout the day.

• Participate in live Q&A sessions
• “Walk the floor” in our virtual exhibition hall
• Live-chat with peers and vendors in the booth
• Download valuable resources
• Re-watch your favorite talks

The C&EN virtual symposium provides a perfect blend of interactivity and convenience. Build your personal agenda ahead of time; if you can’t attend the live symposium, watch replays on-demand at your convenience.


Speakers:

Show Resources
Agenda
All times are Pacific Time
  • SEP 16, 2015 05:00 AM PDT
    Speaker: Mark Blaskovich
  • SEP 16, 2015 06:00 AM PDT
    Speaker: Enoch Huang
  • SEP 16, 2015 07:00 AM PDT
    Speaker: Vic Myer
  • SEP 16, 2015 07:00 AM PDT
    Speaker: Sean Ekins
  • SEP 16, 2015 08:00 AM PDT
    Speaker: Lisa Marcaurelle
  • SEP 16, 2015 09:00 AM PDT
    Speaker: Robert Plenge
  • SEP 16, 2015 10:00 AM PDT
    Speaker: Christopher Austin
  • SEP 16, 2015 11:00 AM PDT
    Speaker: Emily Balskus
  • SEP 16, 2015 12:00 PM PDT
    Speaker: Hagop Youssoufian
  • SEP 16, 2015 12:00 PM PDT
    Speaker: Christina White
  • SEP 16, 2015 01:00 PM PDT
    Speaker: Derek Lowe
  • SEP 16, 2015 02:00 PM PDT
    Speaker: Jeff Blaney
  • SEP 16, 2015 02:00 PM PDT
    Speaker: Nancy Kelley
  • SEP 16, 2015 05:00 AM PDT
    Speaker: Mark Blaskovich
  • SEP 16, 2015 06:00 AM PDT
    Speaker: Enoch Huang
  • SEP 16, 2015 07:00 AM PDT
    Speaker: Vic Myer
  • SEP 16, 2015 07:00 AM PDT
    Speaker: Sean Ekins
  • SEP 16, 2015 08:00 AM PDT
    Speaker: Lisa Marcaurelle
  • SEP 16, 2015 09:00 AM PDT
    Speaker: Robert Plenge
  • SEP 16, 2015 10:00 AM PDT
    Speaker: Christopher Austin
  • SEP 16, 2015 11:00 AM PDT
    Speaker: Emily Balskus
  • SEP 16, 2015 12:00 PM PDT
    Speaker: Hagop Youssoufian
  • SEP 16, 2015 12:00 PM PDT
    Speaker: Christina White
  • SEP 16, 2015 01:00 PM PDT
    Speaker: Derek Lowe
  • SEP 16, 2015 02:00 PM PDT
    Speaker: Jeff Blaney
  • SEP 16, 2015 02:00 PM PDT
    Speaker: Nancy Kelley
Speakers

  • Christopher Austin
    Director, National Center for Advancing Translational Sciences
    Biography
      Christopher Austin is Director of the National Center for Advancing Translational Sciences (NCATS) at the U.S. National Institutes of Health. NCATS' mission is to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. Before becoming NCATS Director in September 2012, he was Director of the NCATS Division of Preclinical Innovation, which focuses on translating basic science discoveries into new treatments, particularly for rare and neglected diseases, and developing new technologies and paradigms to improve the efficiency of therapeutic and diagnostic development. In this role, he founded and directed numerous initiatives including the NIH Chemical Genomics Center (NCGC), the Therapeutics for Rare and Neglected Diseases (TRND) program, and the Toxicology in the 21st Century (Tox21) program. Before joining NIH in 2002, Dr. Austin directed research programs at Merck, with a particular focus on schizophrenia. Austin earned an A.B. in biology from Princeton University and an M.D. from Harvard Medical School.
    • Emily Balskus
      Associate Professor, Harvard University's Department of Chemistry and Chemical Biology
      Biography
        Emily Balskus is an Associate Professor in Harvard University's Department of Chemistry and Chemical Biology (CCB) leading a research group interested in problems found at the intersection of chemistry and microbiology. She began her scientific career at Williams College, graduating in 2002 as valedictorian with highest honors in chemistry. After spending a year at the University of Cambridge as a Churchill Scholar, she pursued graduate studies in synthetic chemistry and asymmetric catalysis at Harvard under Prof. Eric Jacobsen, receiving her PhD in 2008. From 2008-2011 Emily was an NIH postdoctoral fellow at Harvard Medical School in the lab of Prof. Christopher T. Walsh, where she studied the biosynthesis of bacterial sunscreens. She has also received training in microbiology at the Marine Biology Lab at Woods Hole. Emily's research program seeks to both explore and expand the chemical diversity of microorganisms. By combining an understanding of enzyme mechanism with bioinformatics to rapidly identify new metabolic pathways in microbial genomes, her group has discovered enzymatic chemistry of biological importance as well as transformations that will inspire synthetic chemists and provide new tools for biocatalysis and biological engineering. They are also studying the roles played by these enzymatic reactions in host microbes and microbial communities. Finally, her lab is developing new approaches for manipulating chemical processes in individual microorganisms and the complex communities they inhabit. Overall, Emily's goal is to integrate the fields of chemistry and microbiology in ways that will transform both our understanding of the biology of microbes and microbial communities as well as our ability to harness these organisms for chemical production.
      • Jeff Blaney
        Director of Computational Chemistry & Cheminformatics Genentech
        Biography
          Jeff Blaney is the at Genentech. Prior to Genentech, Dr. Blaney held executive positions at SGX Pharmaceuticals, Metaphorics, DuPont Pharmaceuticals, and Chiron… just to name a few. Dr. Blaney obtained his Ph.D. in Pharmaceutical Chemistry from the University of California, San Francisco. Dr. Blaney has many years of experience in industrial drug discovery research, focusing on structure-based design, high-throughput docking, combinatorial library design, and chemical informatics.
        • Mark Blaskovich
          Program Coordinator: Community for Open Antimicrobial Drug Discovery, University of Queensland
          Biography
            Dr. Mark Blaskovich is Program Coordinator: Hit Validation & Chemistry for the Community for Open Antimicrobial Drug Discovery, and a Senior Research Officer at the Institute for Molecular Bioscience at The University of Queensland. He has extensive medicinal chemistry expertise and over 15 years of industrial drug development experience, most recently as Chief Operating Officer at Mimetica (Australia), where he managed the drug discovery and development program for melanocortin-5 receptor antagonists leading to a compound currently in Phase II human trials for treatment of acne. In his previous role at CEPTYR (Seattle) he led a multidisciplinary team that developed a preclinical candidate for protein tyrosine phosphatase 1B, while at Molecumetics (Seattle) he headed a $2m/yr industrial collaboration on peptidomimetic compounds targeting proteases and GPCRs. Since starting at The University of Queensland, Mark has been working on developing new antibiotics to treat drug resistant pathogens. He has published over thirty articles, is an inventor on eight patent families with over 100 granted and pending applications, and is author of 'The Handbook on Syntheses of Amino Acids'.
          • Sean Ekins
            CEO, Collaborations Pharmaceuticals
            Biography
              Sean has experience from several large pharma, small companies and software companies. In addition to the companies he works for, he is Adjunct Professor, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill; Adjunct Associate Professor, School of Pharmacy Department of Pharmaceutical Sciences, University of Maryland and Adjunct Professor in the Department of Pharmacology at Rutgers University- Robert Wood Johnson Medical School, Piscataway, NJ. Sean is on the editorial boards of the Drug Discovery Today and Pharmaceutical Research. He has authored or co-authored >230 peer reviewed papers and book chapters as well as edited four books and a book series for Wiley. Sean co-developed several mobile apps with Dr. Alex Clark and has been awarded multiple NIH grants. He is interested in the application of big and small data for rare and neglected disease drug discovery.
            • Enoch Huang
              Executive Director, Computational Sciences, Pfizer
              Biography
                Enoch S. Huang received an AB in Molecular Biology from Princeton University and a PhD in Structural Biology from Stanford University, where he was a National Science Foundation Pre-doctoral Fellow in the laboratory of Prof. Michael Levitt (2013 Nobel Prize in Chemistry). He was appointed a Jane Coffin Childs Fellow at Washington University School of Medicine (St. Louis), where he developed methods for protein structure prediction with Prof. Jay Ponder. In 1999, Enoch joined Cereon Genomics as a Computational Biologist. The following year, he accepted a position at Pfizer R&D in Cambridge as a Senior Research Scientist. In 2001, he became department head of the newly formed Molecular Informatics group and joined the site management team. In 2007 he accepted a global role as Head of the Computational Sciences Center of Emphasis. External to Pfizer, Enoch has been an Adjunct Assistant Professor of Bioinformatics at Boston University since 2001. He currently serves on the Editorial Advisory Board for Drug Discovery Today, the Bioinformatics Professional Advisory Committee at Brandeis University, and the Industry Advisory Board of the International Society for Computational Biology. He has also served on the external advisory board of the Bioinformatics Program at the Rochester Institute of Technology, the external advisory committee for the Research Informatics Solutions group at the Minnesota Supercomputing Institute, the program committee of the Systems Biology discussion group at the New York Academy of Sciences, the Steering Group for the Life Sciences Informatics Committee of the Massachusetts Biotechnology Council, and on Special Emphasis Panels of study sections for the National Institutes of Health. He is the author of over 30 research articles, scientific reviews, and book chapters and released the Open Source software package PFAAT.
              • Nancy Kelley
                Founder, Nancy J Kelley + Associates
                Biography
                  Nancy J Kelley is a senior executive and lawyer with exceptional leadership ability and management skills. She has over twenty years of executive management and board experience in starting, growing, and restructuring organizations, raising capital, recruiting diverse management teams, creating and implementing strategic plans, developing real estate, developing internet based information platforms, data warehouses and marketing/branding. She has a particularly deep understanding of the healthcare, life science and research fields and has in-depth knowledge of the related legal, business, government, non-profit and academic sectors. Nancy J Kelley served as the Founding Executive Director of the New York Genome Center. From its establishment in 2010 by its 11 Institutional Founding Members, she led the Center from a start up through its current stage of becoming a fully operational, world class genomics research center and provider of cutting edge sequencing and bioinformatics services, raising $110 million to do so. Many of NYGC's foundational elements, such as its Pilot Laboratory at Rockefeller University, the NYGC Innovation Center, and key clinical and technology partnerships, were established under her leadership. Ms. Kelley oversaw the selection and build out of NYGC's permanent facility at 101 Avenue of the Americas in New York City, which opened in September, 2013. She also recruited a large scientific and management team as well as several of the Center's Associate Members.
                • Derek Lowe
                  Research Fellow, Vertex
                  Biography
                    Dr. Derek Lowe is a chemistry blogger and medicinal chemist working on preclinical drug discovery, currently as a Research Fellow at Vertex Pharmaceuticals. Lowe (born in Harrisburg, Arkansas) got his BA from Hendrix College and his PhD in organic chemistry from Duke University, doing his doctoral research studying the organic synthesis of natural products, before spending time in Germany on a Humboldt Fellowship on his post-doc. Lowe was apparently the first person to blog from inside the drug industry, and appears be one of the first science bloggers.He maintains an online presence, commenting on drug discovery and the pharmaceutical industry in his blog "In the Pipeline"."In the Pipeline" attracts a wide readership, getting approximately 15,000 to 20,000 page views on a typical weekday.He also regularly writes columns about organic and medicinal chemistry, detailing the trends and challenges of drug development, in the Royal Society of Chemistry periodicalChemistry World. He serves on the editorial board of ACS Medicinal Chemistry Letters and on the advisory board of Chemical & Engineering News.
                  • Lisa Marcaurelle
                    Vice President, Discovery Chemistry, H3 Biomedicine
                    Biography
                      Dr. Lisa Marcaurelle joined H3 Biomedicine as Vice President of Discovery Chemistry in April 2011, from the Broad Institute, where she was Director of Synthetic Chemistry in the Chemical Biology Platform. During her four years at the Broad Institute, Lisa established a synthetic platform for the large-scale production of diversity-oriented synthesis (DOS) libraries, generating a collection of more than 100,000 small molecules for use in high-throughput screening. While at the Broad, Lisa also served as a Project Leader for the Harvard/Broad Center for Chemical Methodology and Library Development (CMLD). Prior to joining the Broad, she worked at Infinity Pharmaceuticals from 2002 to 2007, where she was engaged in the synthesis of numerous DOS libraries and participated in oncology-focused medicinal chemistry efforts. Lisa completed her post-doctoral research at the Massachusetts Institute of Technology, working with Professor Peter Seeberger. She obtained a Ph.D. in chemistry from the University of California, Berkeley, working under the guidance of Professor Carolyn Bertozzi. Lisa earned a B.A. in chemistry from the College of the Holy Cross in Worcester, MA.
                    • Vic Myer
                      Chief Technology Officer, Editas
                      Biography
                        Vic Myer is the chief technology officer for Editas Medicine, a leading genome editing company bringing specific expertise in CRISPR/Cas9 and TALENs technologies. Prior to Editas, Vic served as executive director and Cambridge site head for the developmental and molecular pathways department at the Novartis Institutes for Biomedical Research Incorporated (NIBR), where he also served as a research investigator, led the high throughput biology team and oversaw the target discovery technologies platform. Vic was also a founding scientist and group leader at Akceli, Inc., a venture-backed systems-biology company focusing on commercialization of a high-throughput cell-based micro-array technology, served as senior scientist for Millennium Pharmaceuticals and held various roles at Corning, Inc. Vic received his B.S. in biology (biochemistry) from Cornell University and his Ph.D. in molecular biophysics and biochemistry from Yale University.
                      • Robert Plenge
                        Vice President, Merck
                        Biography
                          Robert is Vice President at MRL in Boston, MA. He is founder and worldwide Head of the department of Genetics & Pharmacogenomics (GpGx). In April 2015, Robert launched a new Translation Medicine department, which includes GpGx. The Translational Medicine department consists of more than 300 scientists responsible for translating basic science into therapeutic trials. Together, we identify novel targets and pathways based on human genetics and discovery medicine studies in humans. As therapeutic compounds advance through the drug discovery process, we develop biomarkers using advancing imaging techniques and molecular assays to robustly measure target modulation in humans. Our team of clinical pharmacologists is responsible for conducting first-in-human studies, clinical proof-of-concept trials, and additional Phase I/IIa studies to support registration in all therapeutic areas outside of oncology.
                        • Christina White
                          Professor of Chemistry, University of Illinois
                          Biography
                            M. Christina White was born in Athens, Greece. She received a B.A. degree in biochemistry with highest honors from Smith College working with Stuart Rosenfeld. After a one-year stint in the biology graduate program working with Christian Anfinsen, she received her Ph. D. degree from Johns Hopkins University in chemistry with Gary Posner as an ACS Medicinal Chemistry predoctoral fellow. She conducted postdoctoral studies at Harvard University with Eric Jacobsen as an NIH postdoctoral fellow and is currently a Professor of Chemistry at the University of Illinois at Urbana-Champaign. The White group aims to discover selective, catalytic C-H oxidation, amination, and alkylation reactions for use in organic synthesis. They have contributed novel palladium/sulfoxide [(http://en.wikipedia.org/wiki/White_catalyst), Aldrich, Strem, and TCI] and iron catalysts [(http://en.wikipedia.org/wiki/White-Chen_Catalyst) Aldrich,Strem] that functionalize allylic and aliphatic C-H bonds under preparative conditions with predictable site-selectivities and without the requirement for directing groups. These catalysts led to the discovery of a code for differential reactivity between C-H bonds based on electronic, steric, and stereoelectronic effects that has been demonstrated to be general across a range of different aliphatic C-H oxidation reactions. Using these catalysts, seminal demonstrations of site-selective and -divergent C-H oxidations in complex molecules pioneered the concept of late-stage functionalization.
                          • Hagop Youssoufian
                            Chief Medical Officer, BIND Therapeutics
                            Biography
                              Hagop Youssoufian, M.Sc., M.D., has served as BIND Therapeutic's Chief Medical Officer since November 2014 and additionally has led Regulatory Affairs and Quality Assurance activities since March 2015. Prior to joining BIND, Dr. Youssoufian served as Executive Vice President of Research and Development at Progenics Pharmaceuticals and was previously President of Research and Development and Chief Medical Officer at Ziopharm Oncology. Dr. Youssoufian has also held senior medical and R&D leadership positions at Lilly, Imclone Systems, Sanofi Aventis and Bristol-Myers Squibb. He completed fellowships in Clinical Genetics at Johns Hopkins and in Hematology-Oncology at Massachusetts General Hospital, and was a Visiting Scientist at Whitehead Institute, MIT. Dr. Youssoufian has served on the faculties at Baylor College of Medicine and Harvard Medical School and received his M.Sc. and M.D. from the University of Massachusetts Medical School and a B.S. from Boston College.
                            Sponsored By

                            For information on becoming a sponsor or exhibitor, please click here.


                            Help

                            General LabRoots Questions

                            For bugs, spam, technical support or questions please call +1-714-463-4673 or email support@labroots.com  
                            Contact us

                            Virtual Events and Webinars

                            Supported Configurations

                            • Operating System Internet Explorer Firefox Chrome Safari
                              Vista IE8+ FF10+ Chrome15+
                              Windows 7 IE8+ FF10+ Chrome15+
                              Windows 8 IE10 FF10+ Chrome15+
                              Mac OS X   FF10+ Chrome15+ Safari5.1+
                            • Cookie settings: session cookies enabled
                            • Browser configuration must have JavaScript enabled
                            • Adobe Flash player 10.2 or later

                            To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                            Internet Connection

                            • A minimum of 100Kbps is recommended for audio-only events
                            • A minimum of 300Kbps is recommended for speaker on-video events

                            Computer Equipment

                            • Screen Resolution: Minimum 1024x768
                            • Video Card: 65,000 colors minimum
                            • Sound card and speakers (or headphones) for hearing webcast in full format
                            • Audio Card: 16-bit minimum
                            • RAM: 512MB of free RAM

                            Firewall Protocol

                            • HTTP on port 80 or HTTPS on port 443
                            • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                            • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                            Work-At-Home Attendees

                            • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                            For A Seamless Experience

                            When using a mobile device, FREE Mobile Apps are available:

                            - For viewing Webinars:

                            - For viewing Virtual Events

                            Attendee Guide

                            • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                            Virtual Event and Webinar Support:

                            Continuing Education (CME/CE) Support

                            Loading Comments...
                            Show Resources